Evidence map›Paper›PMID 38574891›Full record

ArticleThe Journal of biological chemistry2024

Interplay of RAP2 GTPase and the cytoskeleton in Hippo pathway regulation.

Chenzhou Wu, Xiaomin Cai, Ying Wang, Carlos D Rodriguez, Giorgia Zoaldi, Lydia Herrmann, Chun-Yuh Huang, Xiaoqiong Wang, Viraj R Sanghvi, Rongze O Lu and 1 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Mechanobiology of the Hippo-YAP Signaling Network.Cold Spring Harbor perspectives in biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. The Hippo Pathway in Breast Cancer: The Extracellular Matrix and Hypoxia.International journal of molecular sciences · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Chenzhou WuDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Xiaomin CaiDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Ying WangDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Carlos D RodriguezDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Giorgia ZoaldiDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Lydia HerrmannDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Chun-Yuh HuangDepartment of Biomedical Engineering, University of Miami, Coral Gables, Florida, USA.
Xiaoqiong WangSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA; Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
Viraj R SanghviSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA; Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York City, New York, USA.
Rongze O LuDepartment of Neurological Surgery, Brain Tumor Center, Helen Diller Cancer Center, UCSF, San Francisco, California, USA.
Zhipeng MengDepartment of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, Florida, USA; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: zxm282@miami.edu.
University of Miami · USNeurological Surgery · US

Funding

Roles of mechanotransduction in organ regeneration and fibrosisR35GM142504 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MENG, ZHIPENG · 2021 to 2025
$2.0M
Regulation of Macrophage- and Microglia-mediated STING Signaling in GlioblastomaR01NS126501 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rongze Olivia Lu · 2022 to 2026
$1.9M
Comprehensive Research Experiences to Advance Training and Education (CREATE) for Future Cancer ResearchersR25CA261632 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Kerry L Burnstein, Claude-Henry Volmar · 2021 to 2026
$1.7M
NCI NIH HHS R25 CA261632NIGMS NIH HHS R35 GM142504NINDS NIH HHS R01 NS126501
6 · The paper itself

Abstract

The Hippo signaling is instrumental in regulating organ size, regeneration, and carcinogenesis. The cytoskeleton emerges as a primary Hippo signaling modulator. Its structural alterations in response to environmental and intrinsic stimuli control Hippo signaling pathway activity. However, the precise mechanisms underlying the cytoskeleton regulation of Hippo signaling are not fully understood. RAP2 GTPase is known to mediate the mechanoresponses of Hippo signaling via activating the core Hippo kinases LATS1/2 through MAP4Ks and MST1/2. Here we show the pivotal role of the reciprocal regulation between RAP2 GTPase and the cytoskeleton in Hippo signaling. RAP2 deletion undermines the responses of the Hippo pathway to external cues tied to RhoA GTPase inhibition and actin cytoskeleton remodeling, such as energy stress and serum deprivation. Notably, RhoA inhibitors and actin disruptors fail to activate LATS1/2 effectively in RAP2-deficient cells. RNA sequencing highlighted differential regulation of both actin and microtubule networks by RAP2 gene deletion. Consistently, Taxol, a microtubule-stabilizing agent, was less effective in activating LATS1/2 and inhibiting cell growth in RAP2 and MAP4K4/6/7 knockout cells. In summary, our findings position RAP2 as a central integrator of cytoskeletal signals for Hippo signaling, which offers new avenues for understanding Hippo regulation and therapeutic interventions in Hippo-impaired cancers.

Indexed as

Hippo Signaling PathwayProtein Serine-Threonine KinasesSignal TransductionAnimalsCytoskeletonHumansMiceMicrotubulesPaclitaxelPhosphorylationrap GTP-Binding ProteinsrhoA GTP-Binding ProteinTumor Suppressor ProteinsLATS1 protein, humanLATS2 protein, humanPaclitaxelProtein Serine-Threonine KinasesRAP2A protein, humanrap GTP-Binding ProteinsrhoA GTP-Binding ProteinTumor Suppressor Proteinscytoskeletonenergy stressHippo signalingMAP4KmechanotransductionRAP2 GTPase

Identifiers

PMID38574891
PMCPMC11067347
OpenAlexW4393410371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.